Deal Team

Corporate

Pfizer in its $3.3 billion sale of ordinary shares in Haleon to institutional investors

On March 19, 2025, Pfizer Inc. (NYSE: PFE) announced the sale of approximately 618 million ordinary shares in Haleon plc (LSE/NYSE: HLN) to institutional investors (the “Offering”) in an unregistered offering pursuant to exemptions from registration under the Securities Act of 1933, at a price of 385 pence ($5.01) per ordinary share.  In connection with the Offering, Haleon will also repurchase approximately 44 million ordinary shares having an aggregate value of approximately £170 million ($220 million) directly from Pfizer (the “Share Buyback”).

The aggregate amount of the Offering and Share Buyback is approximately £2.5 billion ($3.3 billion).  Following the settlement of the Offering and the Share Buyback, Pfizer will have fully exited its position in Haleon, which today represents approximately 7.3% of Haleon’s issued share capital.

Wachtell, Lipton, Rosen & Katz is serving as legal advisor to Pfizer.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.